Drug Type TCR therapy |
Synonyms ZI KL1 1 |
Target |
Mechanism KKLC1 inhibitors(Kita-Kyushu lung cancer antigen-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Zelluna Immunotherapy ASStartup |
Active Organization Zelluna Immunotherapy ASStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | NO | Zelluna Immunotherapy ASStartup | 28 Aug 2024 |
Lung Cancer | Preclinical | NO | Zelluna Immunotherapy ASStartup | 28 Aug 2024 |
Pancreatic Cancer | Preclinical | NO | Zelluna Immunotherapy ASStartup | 28 Aug 2024 |
Stomach Cancer | Preclinical | NO | Zelluna Immunotherapy ASStartup | 28 Aug 2024 |
Uterine Cervical Cancer | Preclinical | NO | Zelluna Immunotherapy ASStartup | 28 Aug 2024 |